Reuters logo
BRIEF-EQL Pharma receives SEK 6.3 mln in capital via exercise of warrants
December 16, 2016 / 1:33 PM / 9 months ago

BRIEF-EQL Pharma receives SEK 6.3 mln in capital via exercise of warrants

Dec 16 (Reuters) - EQL Pharma AB :

* Cadila Pharmaceuticals Limited has exercised 973,000 warrants of TO3

* Cadila received 2 million TO3 with a strike price 6.5 Swedish crowns and duration until December 15, 2016 in connection with the directed share issue in October 2015

* A total of 973,000 warrants TO 3 exercised (about 49 percent of all TO 3), which means EQL Pharma will receive about 6.3 million Swedish crowns ($672,466.24)

* Cadila have, following the subscription of the new shares, 29,9% of capital and votes of EQL Pharma AB

Source text: bit.ly/2hBM4xe

Further company coverage:

$1 = 9.3685 Swedish crowns Gdynia Newsroom

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below